Characteristics of microbiomes of the saliva, duodenal bulb, and descending portion of superficial nonampullary duodenal epithelial tumors

Shibata, Hiroyuki; Yamamoto, Kenta; Hirose, Takashi; Furune, Satoshi; Kakushima, Naomi; Furukawa, Kazuhiro; Nakamura, Masanao; Honda, Takashi; Fujishiro, Mitsuhiro; Kawashima, Hiroki

doi:10.1016/j.dld.2024.01.212

Digestive and Liver Disease

2024

DOI: 10.1016/j.dld.2024.01.212

|View full text |Cite

Characteristics of microbiomes of the saliva, duodenal bulb, and descending portion of superficial nonampullary duodenal epithelial tumors

Hiroyuki Shibata,

Kenta Yamamoto,

Takashi Hirose

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Advances in the diagnosis and treatment of MET-variant digestive tract tumors

Zhang,

Dong,

Gao

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

The receptor tyrosine kinase encoded by the MET gene plays an important role in various cellular processes such as growth, survival, migration and angiogenesis, and its abnormal activation is closely related to the occurrence and development of various tumors. This article reviews the recent advances in diagnosis and treatment of MET-variant digestive tract tumors. In terms of diagnosis, the application of next-generation sequencing technology and liquid biopsy technology makes the detection of MET variants more accurate and efficient, providing a reliable basis for individualized treatment. In terms of treatment, MET inhibitors such as crizotinib and cabotinib have shown good efficacy in clinical trials. In addition, the combination of immunotherapy and MET inhibitors also demonstrated potential synergies, further improving the therapeutic effect. However, the complexity and heterogeneity of drug resistance mechanisms are still one of the difficulties in current research. In the future, it is necessary to further deepen the understanding of the mechanism of MET variation and explore new combination treatment strategies to improve the overall survival rate and quality of life of patients. The diagnosis and treatment of MET-variant digestive tract tumors are moving towards precision and individualization, and have broad application prospects.

show abstract

Advances in the diagnosis and treatment of MET-variant digestive tract tumors

Zhang,

Dong,

Gao

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Characteristics of microbiomes of the saliva, duodenal bulb, and descending portion of superficial nonampullary duodenal epithelial tumors

Cited by 1 publication

References 29 publications

Advances in the diagnosis and treatment of MET-variant digestive tract tumors

Advances in the diagnosis and treatment of MET-variant digestive tract tumors

Contact Info

Product

Resources

About